# Myelodysplastic Syndromes; Cytopenia FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/myelodysplastic-syndromes-cytopenia

> 2 upcoming FDA catalysts in myelodysplastic Syndromes; Cytopenia: elritercept (TAK) on Oct 2029 to Jan 2030 (topline data readout); elritercept (TAK) on October 2029 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Oct 2029 to Jan 2030 | [Elritercept topline data readout](https://sec-api.dev/pdufa/elritercept) | TAK | Myelodysplastic Syndromes; Cytopenia | scheduled | "NCT04419649 (A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-10-30 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04419649)) |
| October 2029 | [Elritercept primary completion](https://sec-api.dev/pdufa/elritercept) | TAK | Myelodysplastic Syndromes; Cytopenia | scheduled | "NCT04419649 (A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-10-30 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04419649)) |

## Drugs

- [Elritercept](https://sec-api.dev/pdufa/elritercept) (TAK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/myelodysplastic-syndromes-cytopenia.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Myelodysplastic Syndromes; Cytopenia FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/myelodysplastic-syndromes-cytopenia

```bibtex
@misc{secapidev_indications_myelodysplastic_syndromes_cytopenia_20261116,
  title        = {Myelodysplastic Syndromes; Cytopenia FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/myelodysplastic-syndromes-cytopenia}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_myelodysplastic_syndromes_cytopenia_20261116","title":"Myelodysplastic Syndromes; Cytopenia FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/myelodysplastic-syndromes-cytopenia","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
